Family Medicine · Gary, IN
NPI
1629193321
Since 2007
Specialty
Family Medicine
Code 207Q00000X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
2054 Grant St
Gary, IN, 46404
Phone (219) 949-7540
Groups this clinician bills Medicare through
Medicare paid, 2024
$71K
2,464 services
Medicare patients, 2024
242
Average age 67
Drug cost, 2024
$1.2M
14,494 prescriptions
Company payments, 2025
$2,057
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul C Okolocha was code J1010 (injection, methylprednisolone acetate, 1 mg), 720 times for 13 patients. In total Paul C Okolocha billed 2,464 services in 52 codes, and Medicare paid $71K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 720 | 13 | $0.09 | $66.36 |
| 99213 Office E&M - Established | Office | 365 | 123 | $56.97 | $21K |
| 99231 Hospital E&M - Subsequent | Facility | 252 | 52 | $35.92 | $9,052 |
| 99214 Office E&M - Established | Office | 212 | 107 | $80.94 | $17K |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 131 | 13 | $0.56 | $72.88 |
| 82962 Clinical Chemistry | Office | 95 | 46 | $3.18 | $302 |
| 96372 Injection Administration | Office | 87 | 18 | $8.03 | $698 |
| 99238 Hospital Discharge Management | Facility | 82 | 59 | $58.92 | $4,831 |
| 80305 Drug Tests | Office | 72 | 46 | $12.22 | $880 |
| 99222 Hospital E&M - Initial | Facility | 66 | 52 | $92.86 | $6,129 |
| 83036 Blood Count | Office | 58 | 41 | $9.39 | $545 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 43 | 13 | $0.85 | $36.46 |
| 99232 Hospital E&M - Subsequent | Facility | 43 | 24 | $58.10 | $2,498 |
| 81002 Clinical Chemistry | Office | 39 | 26 | $3.41 | $133 |
| 36415 Venipuncture Blood Collection | Office | 36 | 36 | $8.45 | $304 |
By year: 2022 $134K for 2,705 services; 2023 $78K for 1,730 services; 2024 $71K for 2,464 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 95 | 46 | $3.18 | $302 |
| 80305 Drug Tests | 72 | 46 | $12.22 | $880 |
| 83036 Blood Count | 58 | 41 | $9.39 | $545 |
| 81002 Clinical Chemistry | 39 | 26 | $3.41 | $133 |
| 36415 Venipuncture Blood Collection | 36 | 36 | $8.45 | $304 |
Medicare prescription drug claims, 2024
In 2024, the drug Paul C Okolocha prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 842 prescriptions and refills. In total Paul C Okolocha wrote 14,494 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 842 | 842 | 152 | $13K |
| Alprazolam Generic | 581 | 581 | 101 | $1,526 |
| Gabapentin Generic | 535 | 627 | 163 | $5,595 |
| Amlodipine Besylate Generic | 483 | 1,129 | 185 | $1,711 |
| Ibuprofen Generic | 419 | 428 | 121 | $3,836 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 320 | 372 | 100 | $8,362 |
| Atorvastatin Calcium Generic | 312 | 583 | 97 | $3,135 |
| Meloxicam Generic | 272 | 322 | 130 | $460 |
| Furosemide Generic | 269 | 516 | 92 | $1,076 |
| Prednisone Generic | 250 | 250 | 138 | $555 |
| Omeprazole Generic | 250 | 400 | 81 | $1,936 |
| Trazodone Hcl Generic | 209 | 254 | 38 | $1,425 |
| Pantoprazole Sodium Generic | 208 | 314 | 75 | $1,864 |
| Tamsulosin Hcl Generic | 202 | 302 | 50 | $1,862 |
| Levothyroxine Sodium Generic | 194 | 272 | 35 | $2,167 |
Brand drugs: 1,538 claims; generic drugs: 12,851 claims; opioid claims: 1,302.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul C Okolocha $2,057 ($2,057 in general payments such as food, travel and fees) from 20 companies. The largest payer was ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) with $379.
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 17 | $379 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $278 |
| Axsome Therapeutics, Inc. AXSM | 8 | $250 |
| Abbott Laboratories ABT | 15 | $162 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 7 | $144 |
| E.R. Squibb & Sons, L.L.C. BMY | 5 | $133 |
| Lundbeck LLC | 5 | $102 |
| Neurocrine BioSciences, Inc. NBIX | 4 | $98.74 |
| Abbvie Inc. ABBV | 5 | $82.42 |
| GlaxoSmithKline, LLC. GSK | 4 | $78.14 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.